HomeComparePTOTF vs PFE

PTOTF vs PFE: Dividend Comparison 2026

PTOTF yields 456.41% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PTOTF wins by $30552.09M in total portfolio value
10 years
PTOTF
PTOTF
● Live price
456.41%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30552.14M
Annual income
$21,350,160,746.31
Full PTOTF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PTOTF vs PFE

📍 PTOTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTOTFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTOTF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTOTF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTOTF
Annual income on $10K today (after 15% tax)
$38,795.07/yr
After 10yr DRIP, annual income (after tax)
$18,147,636,634.36/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PTOTF beats the other by $18,147,614,314.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTOTF + PFE for your $10,000?

PTOTF: 50%PFE: 50%
100% PFE50/50100% PTOTF
Portfolio after 10yr
$15276.10M
Annual income
$10,675,093,502.51/yr
Blended yield
69.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PTOTF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTOTF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTOTFPFE
Forward yield456.41%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$30552.14M$49.6K
Annual income after 10y$21,350,160,746.31$26,258.71
Total dividends collected$29734.28M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PTOTF vs PFE ($10,000, DRIP)

YearPTOTF PortfolioPTOTF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$56,341$45,641.26$9,153$693.39+$47.2KPTOTF
2$300,611$240,325.80$8,593$849.25+$292.0KPTOTF
3$1,520,035$1,198,380.85$8,336$1,066.78+$1.51MPTOTF
4$7,289,609$5,663,172.02$8,437$1,384.80+$7.28MPTOTF
5$33,181,935$25,382,052.97$9,013$1,875.40+$33.17MPTOTF
6$143,483,952$107,979,282.43$10,306$2,680.72+$143.47MPTOTF
7$589,901,247$436,373,418.36$12,820$4,101.38+$589.89MPTOTF
8$2,307,875,529$1,676,681,194.03$17,673$6,826.70+$2307.86MPTOTF
9$8,599,981,677$6,130,554,860.75$27,543$12,591.86+$8599.95MPTOTF
10$30,552,141,140$21,350,160,746.31$49,560$26,258.71+$30552.09MPTOTF

PTOTF vs PFE: Complete Analysis 2026

PTOTFStock

Patriot One Technologies Inc. engages in the research, development, and commercialization of threat detection solutions worldwide. It operates through Patriot and Xtract segments. The Patriot segment develops and commercializes a platform of artificial intelligence (AI) powered threat detection technologies. The Xtract segment develops and commercializes AI solutions. The company's products include PATSCAN VRS Video Recognition Software that combines digital cameras and artificial intelligence to automate the detection of visible weapon threats, fights, and health and safety issues; and PATSCAN Multi-Sensor Gateway, an autonomous detection system that detects threats on individuals carrying concealed guns, knives, or related threat objects into secured private or public spaces, and can be installed at schools, stadiums, concert halls, shopping centers, and other entryways into private, public, or secured buildings. It also develops PATSCAN Cognitive Microwave Radar (CMR), a system to detect concealed guns and knives utilizing microwave radar technology coupled with custom machine learning/AI software. The company was formerly known as Clear Mountain Resources Corp. and changed its name to Patriot One Technologies Inc. Patriot One Technologies Inc. was founded in 2016 and is headquartered in Toronto, Canada.

Full PTOTF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PTOTF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTOTF vs SCHDPTOTF vs JEPIPTOTF vs OPTOTF vs KOPTOTF vs MAINPTOTF vs JNJPTOTF vs MRKPTOTF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.